Entinostat is a synthetic small-molecule histone deacetylase (HDAC) inhibitor investigated primarily for oncology applications. It belongs to the benzamide class of HDAC inhibitors and has been studied as a targeted epigenetic therapy in several types of cancer.
Entinostat selectively inhibits class I HDAC enzymes, particularly HDAC1, HDAC2 and HDAC3. By inhibiting histone deacetylation, Entinostat can alter chromatin structure and gene expression, potentially affecting cancer-cell proliferation, differentiation and survival.
Entinostat is also known by the development code MS-275. It is an orally active benzamide HDAC inhibitor that has been investigated in clinical and preclinical oncology research.
Entinostat has the molecular formula C₂₁H₂₃N₃O₂ and a molecular weight of approximately 349.43 g/mol.
Swapnroop Drugs and Pharmaceuticals provides Entinostat API for qualified pharmaceutical manufacturing, formulation development, oncology research and pharmaceutical sourcing requirements.
Entinostat is a specialized oncology API relevant to epigenetic drug research and HDAC inhibitor development.
Entinostat inhibits class I histone deacetylases (HDACs), particularly HDAC1, HDAC2 and HDAC3.
HDAC inhibition increases histone acetylation and can modify chromatin accessibility and gene transcription. This may influence cellular processes including:
Entinostat is associated with:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |